Protagenic Therapeutics, Inc. (PTIX)
Nasdaq · Healthcare · Biotechnology
$0.63−3.08%as of Nov 5, 2026, 4:50 AM ET
- Market cap
- $1.1M
- P/E (trailing)
- 0.3
- 52-week range
- $0.128 – $2.38
- 52-week change
- −69.63%
- EPS (trailing)
- $2.23
Fiscal year to Mar 2026
- Revenue
- $0K
- Net income
- $1.4M
- Diluted EPS
- $0.59
- Free cash flow
- −$2.8M
From the company’s annual report on SEC EDGAR.
About Protagenic Therapeutics, Inc.
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. The company was founded in 2004 and is based in New York, New York.
Headquarters: New York, United States · 2 employees · protagenic.com